You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥-B(02137.HK)與健康元集團攜手推進BRII-693研發及商業化

格隆匯7月4日丨騰盛博藥-B(02137.HK)發佈公告,公司全資子公司Brii Biosciences, Inc.(“騰盛博藥美國”)已與健康元藥業集團股份有限公司(“健康元集團”)簽署知識產權許可及技術轉移協議。根據本協議約定,健康元集團將從騰盛博藥美國獲得在中國大陸、中國香港、中國澳門和中國臺灣(合稱“大中華地區”)對BRII-693進行研究、開發和商業化的獨佔許可。根據本協議約定,健康元集團將全面負責 BRII-693在大中華區的開發、監管審批和商業化。作爲交易對價,騰盛博藥美國已收到首付款,後續在達成相關里程碑事件時將收到額外的開發和商業化里程碑付款,並將根據BRII-693的產品淨銷售額按約定比例獲得銷售分成。

公司董事長兼首席執行官洪志博士表示:“大中華地區的抗菌藥耐藥威脅日益嚴重,凸顯了新型醫院抗生素的迫切性。健康元集團在醫院抗生素的生產和商業化方面有着久經考驗的能力,我們找到了加速BRII-693開發和商業化的理想合作夥伴。這次合作使我們能夠爲面臨危及生命感染的中國患者提供重症監護藥物。”

健康元集團首席執行官林楠棋先生表示:“騰盛博藥在創新藥物研發領域深耕已久、實力深厚。BRII-693項目依託騰盛博藥成熟的研發體系推進,展現了高度的專業性與創新性,該項目在疾病治療潛力、藥效學特性和藥代動力學表現等方面均顯示出積極結果,有望成爲Best-in-Class藥物,切實解決臨牀上亟待滿足的治療需求。我們十分看好BRII693的臨牀開發前景,此次合作進一步強化了健康元集團在抗感染管線的戰略佈局。期待這款藥物能早日上市,爲患者提供更多優質治療選擇。 ”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account